Alzheimer's is a progressive and fatal disease, a devastating illness that affects millions of Americans and their families. As new and better treatments for Alzheimer's disease receive FDA approval, swift access to these disease-modifying therapies is crucial for those who have been diagnosed.

There is a growing consensus in the scientific and medical communities about the clinical benefits of the removal of amyloid plaque from the brain for people living with mild cognitive impairment and early-stage Alzheimer’s disease. Clinical trial results indicate treatments taken in the early stages of Alzheimer’s can deliver more time to participate in daily life and remain Independent.

In 2022 the Centers for Medicare & Medicaid Services (CMS) issued a national coverage determination (NCD) that severely restricts patient access to FDA-approved medications that target amyloid plaque. Recently, there was a request to CMS to allow access for patients  with Alzheimer’s disease., CMS declined to take action.

We are the American Alzheimer’s Alliance, and we are calling on Congress and the Biden Administration to tell the Centers for Medicare & Medicaid Services (CMS) to reconsider the national coverage determination to allow access to medicines for patients with Alzheimer’s Disease.